Bird Flu News and Research RSS Feed - Bird Flu News and Research Twitter

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains. [More]
Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
TSRI scientists describe severe immune overreaction caused by flu infections

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
Frost & Sullivan: Healthcare acquired infections drive hand hygiene market in Western Europe

Frost & Sullivan: Healthcare acquired infections drive hand hygiene market in Western Europe

The need to prevent and control healthcare acquired infections (HCAI) across Europe, which results in 4.5 to 5 million cases annually, is driving the hand hygiene market in Western Europe. Outbreaks of norovirus and bird flu over the past five years have also served to highlight the importance of hand hygiene in containing infectious diseases. Hand hygiene product manufacturers should take advantage of these trends by offering a one-stop solution for all disinfection requirements. [More]
Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). [More]
Internet surveillance helps detect infectious diseases earlier than traditional surveillance methods

Internet surveillance helps detect infectious diseases earlier than traditional surveillance methods

The habit of Googling for an online diagnosis before visiting a GP can provide early warning of an infectious disease epidemic. [More]
New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza - the virus that causes the flu - appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications. [More]
European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide. [More]

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

... [More]

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

​A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture. [More]
Scientists aim at protecting adults from virulent strain of avian influenza virus

Scientists aim at protecting adults from virulent strain of avian influenza virus

Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus. [More]

Scientists are preparing for possible pandemic spread of new bird flu strain

Scientists at Saint Louis University are preparing for the potential pandemic spread of a new bird flu strain that caused severe disease in China last spring, joining researchers from seven other Vaccine and Treatment Evaluation Units funded by the National Institutes of Health (NIH) to test vaccines to protect against the illness in adults. [More]

Scientists prepare to test vaccines to protect against new bird flu strain

Scientists at Group Health Research Institute are preparing for the potential pandemic spread of a new bird flu strain that caused severe disease in China earlier this year, joining researchers from seven other Vaccine and Treatment Evaluation Units funded by the National Institutes of Health to test vaccines to protect against the illness in adults. [More]
Researcher characterises influenza A viruses in gulls and ducks

Researcher characterises influenza A viruses in gulls and ducks

Ducks and gulls are the natural hosts of influenza A virus. Ragnhild Tønnessen's PhD research project has characterised influenza A viruses in gulls and ducks in Norway. Her discoveries may lead to a better understanding of the epidemiology and host adaptation of influenza A virus. [More]
BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

BiondVax announced today that priming with universal flu vaccine before boosting with a conventional bird flu H5N1 vaccine (containing a single strain from Clade 1) resulted in mice exhibiting a significantly higher level of immunity to the strain contained in the conventional bird flu vaccine and in addition, broadened immunity to other H5N1 flu strains (from Clade 2). [More]
Strategy that dismantles flu viral genome in human lung cells ensures safe research

Strategy that dismantles flu viral genome in human lung cells ensures safe research

​A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai. [More]

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates. [More]
Seattle researchers map critical molecules that regulate inflammation during flu infection

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection. [More]
Study describes radiologic findings in H7N9 pneumonia

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology. [More]